Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a BioMedWire editorial that examines emerging approaches to treating multiple sclerosis (MS), a chronic autoimmune disease affecting more than 2.9 million people globally. The editorial highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath—the target of the immune attack in MS. According to the announcement, the Lucid-MS program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in MS treatment.
The editorial, disseminated via BioMedWire, underscores the importance of developing therapies that go beyond symptom management. Current MS treatments focus on reducing inflammation or modulating the immune system, but few directly address myelin repair or protection. Lucid-MS, a patented new chemical entity, has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. If successful in human trials, this could represent a paradigm shift in how the disease is managed.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also invented UNBUZZD, an over-the-counter product aimed at reducing alcohol cravings, and retains ownership of 19.84% of Unbuzzd Wellness Inc. (as of March 31, 2026), along with royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The inclusion in the BioMedWire editorial provides visibility for Quantum’s approach and highlights the potential impact of Lucid-MS. For the estimated 2.9 million people living with MS worldwide, a therapy that protects and repairs myelin could slow or halt disease progression, improving quality of life and reducing disability. For the broader biotech industry, success in Phase 2 trials would validate a novel mechanism of action, potentially opening new avenues for treating other demyelinating disorders.
Investors and stakeholders can follow Quantum’s progress through the company’s newsroom at https://ibn.fm/QNTM. The full press release detailing the editorial is available at https://ibn.fm/KdvrI.
